Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q2 FY21 Earnings Presentation
29 slides from Dishman Carbogen Amcis's earnings presentation, Nov 13, 2020
Slide 1: Cover letter to stock exchanges
13th November, 2020 dish man To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. Ref.: S
Slide 2: Quarter ended September 30th, 2020
Quarter ended September 30th, 2020 November 2020
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 20,586 20,436 4,087 5,519 3,660 16,017 17,137 16,948 4,976 4,534 4,453 26.8% 2,945 2,994 4,103 26.3% 25.6% 26.5% 24.3% FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY18 FY19 FY20 FY16 FY17
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
CARBOGEN @dishman (7 ses” QUARTER
Slide 8: Impact due to EDQM Observations and COVID-19
Impact due to EDQM Observations and COVID-19 Cautionary Statement The business was impacted due to European Directorate for the Quality of Medicines & HealthCare (EDQM) issues at the Bavla site for the company’s product Dihydrotachysterol and due to Covid impact on the overall economy. As such, the
Slide 9: Q2 FY21 Result Highlights
Q2 FY21 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 1,458 4,498 4,404 31.2% 801 18.2% Q2FY20 Q2FY21 Q2FY20 Q2FY21 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS 875 7.0 1,135 4.8 18.7% 759 261 5.9% Q2FY20 Q2FY21 Q2FY20 Q2FY21 *EBITDA excluding other income and
Slide 10: H1 FY21 Result Highlights
H1 FY21 RESULT HIGHLIGHTS Net REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 9,511 9,156 2,652 26.8% 1,231 13.5% H1FY20 H1FY21 H1FY20 H1FY21 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS 13.0 15.8% 2,099 1,558 7.6 1,188 1.6% 146 H1FY20 H1FY21 H1FY20 H1FY21 *EBITDA excluding other inco
Slide 11: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q2 FY21 Q2 FY20 YoY % H1 FY21 H1 FY20 YoY % Revenue from Operations 4404.2 4,497.9 -2.1% 9,155.5 9,510.8 -3.7% Other Operating Income -9.4 175.2 -16.6 381.3 Total Revenue 4,394.8 4,673.1 -6.0% 9,138.9 9,892.1 -7.6% COGS 678.9 626.7 8.3% 2,166.3 1,929.3 1
Slide 12: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Sep-20 Sep-19 Particulars (₹ mn) Sep-20 Sep-19 Equity Share Capital 313.6 322.8 Property, plant and equipment 17,142.9 16,092.6 Other Equity 58,112.4 54,489.6 Capital Work in Progress 2,387.2 1,938.5 Right to use Lease Assets 1,697.7 1,660.9 Total - Shar
Slide 13: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q2 FY21 Q2 FY20 YoY % H1 FY21 H1 FY20 YoY % CRAMS (% of total) 80.2% 76.8% 76.7% 76.0% CRAMS- India 59.2 1,125.7 -94.7% 207.0 1,893.1 -89.1% CRAMS – Switzerland, France & China 3,197.4 2,086.8 53.2% 6,287.2 4,718.6 33.2% CRAMS - UK
Slide 14: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue – Q2 FY21 Total Operating Revenue - H1 FY21 CRAMS – 80.2% Marketable Molecules – 19.8% CRAMS – 76.7% Marketable Molecules – 23.3% 1.7% 7.8% 7.5% 2.9% 40.1% 41.4% 59.9% 58.6% 90.5% 89.5% CRAMS - India CRAMS - India CRAMS - Switzerland & France Car
Slide 15: Segment-wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q2 FY21 Q2 FY20 H1 FY21 H1 FY20 CRAMS CRAMS- India - 60.6% - 56.9% CRAMS – Switzerland, France & China 22.0% 21.1% 19.1% 19.5% CRAMS - UK 20.0% 26.7% 17.8% 17.7% Marketable Molecules Carbogen Amcis BV 37.1% 40.3% 34.3% 35.0% Others 15.2% 11.3% 13.8% 10.6
Slide 16: Q2 & H1 FY21 Result Highlights
Q2 & H1 FY21 RESULT HIGHLIGHTS Net Revenue at Rs 4,404.2 mn in Q2 FY21 down by 2.1% YoY CRAMS revenue increased 2.3% YoY primarily due to : CRAMS India revenue decreased by 94.7% YoY, due to lower revenue from company’s Bavla site due to the ongoing EDQM observations. CRAMS Carbogen Amcis AG revenue
Slide 17: Company Overview
CARBOGEN @dishman (7 ses” COMPANY
Slide 18: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 19: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 20: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 21: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 22: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES Focus is on supporting the development process from bench to market Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 23: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 24: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY20 FY20 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 23
Slide 25: Industry Overview
CARBOGEN @dishman (7 ses” INDUSTRY
Slide 26: Top 10 Therapy Areas (US$ bn) - 2019
2019 Global Sales by Therapy Areas Specialty areas dominate sales and growth driven by developed markets 0 20 40 60 80 100 120 140 160 Oncologics 44% 22% 8% 11% 15% $146 bn $97 bn Top 10 Therapy Areas (US$ bn) - 2019 11% Antidiabetics 66% 8% 5% 10% 11% $87 bn 2% Autoimmune Diseases 69% 14% 4% $47 bn
Slide 27: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Developed countries account for >80% of specialty market Specialty: Region Market Share 2019 Region Contribution to Global Growth 81% of all specialty sales from 7 countries 2014-19 2014-19 Absolute growth contribution in LCUS$ Market Specialty 12% 13% 13% US 6% 5% 2
Slide 28: Pharmerging Markets - Oncology Leads Growth
PHARMERGING MARKETS - ONCOLOGY LEADS GROWTH Pharmerging Top 10 therapy areas, value and volume growth 32% 17% Value PPG (%) 14%13% 13%12% 11% 10% 10% 9% 9% 8% 8% 8% 9% 7% 7% 5% 5% 2% 3% 4% 12% 11% 10% 9% 8% Volume PPG (%) 5% 6% 6% 3% 3% 3% 4% 4% 4% 4% 4% 4% 0% 0% 1% -2% -1% Pharmerging Antibacterial
Slide 29: Thank you!
Dishman Dishman Corporate House CARBOGEN AMCIS AG Iscon-Bopal Road, Ambli Hauptstrasse 171 Ahmedabad – 380058 CH-4416 Bubendorf Gujarat, India Switzerland www.dishmangroup.com www.carbogen-amcis.com Thank you! FOR FURTHER QUERIES Mr. Binay Sarda Mr. Harshil Dalal Christensen IR Group CFO P: +91 22 4
Dishman Carbogen Amcis — Q2 FY21 Earnings Presentation on 6ix